Table 2 |
||||
|
ACR responses, DAS28 C-reactive protein, and EULAR28 responses at week 24 |
||||
|
AMG 108 |
||||
|
|
||||
|
Placebo (n = 203) |
50 mg (n = 204) |
125 mg (n = 203) |
250 mg (n = 203) |
|
|
|
||||
|
ACR response, n (%)a |
||||
|
ACR20 |
59 (29.1) |
63 (30.9) (P = 0.746) |
73 (36.0) (P = 0.168) |
82 (40.4) (P = 0.022) |
|
ACR50 |
17 (8.4) |
24 (11.8) (P = 0.323) |
28 (13.8) (P = 0.113) |
41 (20.2) (P < 0.001) |
|
ACR70 |
8 (3.9) |
4 (2.0) (P = 0.259) |
5 (2.5) (P = 0.575) |
12 (5.9) (P = 0.492) |
|
DAS28 CRP, mean change from baselineb |
-0.60 |
-0.69 (P = 0.213) |
-0.92 (P < 0.001) |
-1.18 (P < 0.001) |
|
EULAR28 response, n (%)c |
||||
|
Good |
16 (8%) |
20 (10%) |
28 (13.9%) |
39 (19.5%) |
|
Moderate |
61 (30.7%) |
59 (29.3%) |
76 (37.8%) |
76 (38%) |
|
No response |
122 (61.3%) |
122 (60.7%) |
97 (48.3%) |
85 (42.5%) |
|
|
||||
|
ACR, American College of Rheumatology; CRP, C-reactive protein; DAS28, Disease Activity Score (28-joint count); EULAR28, European League Against Rheumatism (28-joint count). aNonresponder imputation: missing ACR responses were imputed as nonresponder. P values are nominal without multiplicity adjustment, using Fisher's exact test. bObserved cases. P values are comparisons with placebo, using two-sided Wilcoxon rank-sum test. cEULAR28 response is classified as good, moderate, and no response based on the DAS28 ESR at week 24 and the DAS28 ESR improvement from baseline at week 24 [31]. |
||||
|
Cardiel et al. Arthritis Research & Therapy 2010 12:R192 doi:10.1186/ar3163 |
||||
